Artificial intelligence (AI) and related technologies offer new avenues of drug discovery productivity never before possible. These innovative methods not only provide significant value to the biopharma industry but reduce labor costs, upscale output and build more resilient R&D supply chains, especially as policies like the Biosecure Act are raising concerns about overseas partnerships. The use of large language models (LLMs) and the digitization of chemical processes are just two of the many strategies addressing the conventional drug discovery bottlenecks associated with high-throughput screening and new compound creation. In this panel, life science companies and investors will discuss the power of AI and digitalization to transform processes that enhance the efficiency of R&D supply chains and biomanufacturing. These AI-driven tools have the power to help the biopharma industry reach their milestones and meet timelines, and aid in minimizing reliance on foreign CROs.